Sarda Proteins Board to Weigh Fund Raise on Aug 5, 2026

Key development: fund-raise proposal before the board

Sarda Proteins Limited, a mustard oil manufacturer and marketer, has scheduled a meeting of its Board of Directors for Wednesday, August 05, 2026. The company said the board will consider proposals to raise funds through multiple instruments. These include equity shares, convertible bonds, and other securities, along with other equity-linked options.

The disclosure was filed with BSE and signed by Managing Director Shirish Dhirajlal Savaliya. The stated purpose of the meeting is to deliberate on capital structure adjustments and fundraising routes. Separately, the article data also references a plan to issue 350,000 equity shares, indicating that equity issuance is among the actions being considered.

What the company told the exchange

In its BSE disclosure, Sarda Proteins said it is evaluating different fundraising routes. The company specifically mentioned equity shares and other equity-linked securities, alongside convertible bonds and other instruments. No pricing, quantum, or timeline beyond the board meeting date was provided in the information shared.

The company’s communication positions the meeting as a strategic discussion on the capital structure. Such board meetings are typically the first step before final approvals, and the company has already been through an Extraordinary General Meeting (EGM) process recently for other corporate actions.

Recent shareholder approvals: name change and authorised capital

Ahead of the proposed fund-raise discussion, shareholders approved key resolutions at an EGM held on July 30, 2026. Members cleared the change of the company’s name from Sarda Proteins Limited to Fresita Proteins Limited, subject to statutory and regulatory approvals.

At the same EGM, shareholders also approved an increase in authorised share capital to ₹100 crore. This decision follows earlier board disclosures that described a large jump in the authorised equity share capital ceiling, enabling the company to potentially issue more shares in the future if required.

How the authorised capital changed

The company’s disclosures outlined the authorised capital increase from ₹13 crore to ₹100 crore. In share terms, the authorised equity share capital moved from 1.3 crore equity shares of face value ₹10 each to 10 crore equity shares of face value ₹10 each. This kind of expansion does not automatically mean shares are issued, but it provides room for fundraising and other equity actions.

The sequence of events matters because raising funds via equity or equity-linked securities generally requires sufficient authorised capital headroom. With the authorised limit expanded, the company now has greater flexibility to evaluate fundraising instruments.

Management and board reshuffle: July 4, 2026 decisions

Sarda Proteins also reported several senior management and board changes in disclosures related to the board meeting held on July 4, 2026. The board approved the resignation of Chirag Shantilal Thumar as Managing Director. It also appointed Shirish Dhirajlal Savaliya as the new Managing Director for a five-year term, effective July 4, 2026, subject to shareholder approval.

In another change, Yagnik Arvindbhai Satasiya’s designation shifted from Chief Financial Officer (CFO) to Additional Director (Non-Executive) and Chairperson. The company appointed Drashti Harshadbhai Delvadiya as the new Chief Financial Officer. The board also took note of the resignation of three directors, namely Bipinkumar Babubhai Savalia, Khilan Hareshbhai Savaliya, and Chintan Umeshbhai Bhatt, all effective July 4, 2026.

Financial snapshot: Q1FY26 turnaround

Sarda Proteins reported a turnaround in its quarterly performance. In Q1FY26, the company posted net profit of ₹1.6597 crore, compared with a loss of ₹0.4934 crore in the year-ago period. Total revenue climbed to ₹18.474 crore.

The board approved the results and also took several corporate actions around the same period. These included appointing Minal Surendra Jain as an Independent Women Director for five years (effective July 15, 2026, subject to shareholder approval), approving relocation of the registered office, and sanctioning the opening of a new corporate office.

EGM process and key dates

The company fixed July 23, 2026 as the cut-off date for the EGM held on July 30, 2026. The disclosures cited shareholder approvals for the authorised capital increase and name change, subject to statutory and regulatory approvals.

Alongside these approvals, the board meeting scheduled on August 05, 2026 is positioned as the next major checkpoint, where fundraising instruments will be evaluated.

What this could mean for investors and stakeholders

Based on the disclosed agenda, the August 05, 2026 board meeting is focused on funding options rather than an already-finalised issuance plan. The company has cited equity shares, equity-linked securities, and convertible bonds among instruments to be evaluated. Separately, the mention of issuing 350,000 equity shares suggests that an equity issuance may be one of the proposals under consideration, though the disclosure shared does not specify terms.

The company’s recent governance changes are also material. A new Managing Director is in place for a five-year term (subject to shareholder approval), a new CFO has been appointed, and multiple directors have exited. Together with the authorised capital increase to ₹100 crore and the pending name change to Fresita Proteins Limited, these steps reflect a period of restructuring and capital planning.

Market impact: what is known from the disclosures

The disclosures provide concrete corporate events but do not include any stock price reaction, fundraising size, issue price, or utilisation plan. What is clear is that the company has created capacity to raise equity by expanding authorised capital, and it has formally put fundraising instruments on the board agenda.

From an operating perspective, the Q1FY26 profit reversal alongside higher revenue provides recent financial context. However, without additional details on the proposed capital raise and the company’s intended use of proceeds, the market impact remains limited to governance and capital structure signals contained in the filings.

Conclusion

Sarda Proteins Limited has set August 05, 2026 for a board meeting to consider fundraising through equity, convertible bonds, and other securities, as disclosed to BSE by Managing Director Shirish Dhirajlal Savaliya. The meeting follows shareholder approvals on July 30, 2026 for a name change to Fresita Proteins Limited (subject to statutory and regulatory approvals) and an authorised share capital increase to ₹100 crore. The next confirmed milestone is the board’s decision and any subsequent disclosures after the August 05 meeting.